Citizens Financial Group Inc. RI Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Citizens Financial Group Inc. RI raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,130 shares of the biopharmaceutical company’s stock after acquiring an additional 127 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Regeneron Pharmaceuticals were worth $12,749,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. One Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 6.1% in the second quarter. One Capital Management LLC now owns 11,668 shares of the biopharmaceutical company’s stock worth $12,263,000 after purchasing an additional 673 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after acquiring an additional 59,769 shares in the last quarter. Quilter Plc purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $250,000. Plato Investment Management Ltd raised its stake in shares of Regeneron Pharmaceuticals by 6.0% during the second quarter. Plato Investment Management Ltd now owns 2,538 shares of the biopharmaceutical company’s stock valued at $2,668,000 after acquiring an additional 144 shares in the last quarter. Finally, Nia Impact Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $209,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold 10,026 shares of company stock worth $11,498,705 in the last ninety days. Company insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Truist Financial reiterated a “buy” rating and set a $1,200.00 target price (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Barclays boosted their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,109.70.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,153.35 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm’s 50 day simple moving average is $1,124.22 and its 200-day simple moving average is $1,026.46. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The stock has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.07, a PEG ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the business earned $8.79 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.